Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
If you have been looking for a big mover in the US premarket, then I have just what you are looking for…
Clinical stage pharmaceutical company Achieve Life Sciences (NASDAQ:ACHV) has blown every other stock out of the water today with an over 2,000% move higher after the US Patent and Trademark Office granted the company a patent on novel analogs of cytisinicline, a process for their preparation, and their use in the prevention or treatment of CNS and addictive disorders.
Achieve's shares have skyrocketed 2586.67%, trading at $16.12 per share after closing yesterdays trading session at just $0.60.
“While smoking cessation and nicotine addiction continue to be our primary focus, it is critically important that we continue to expand our intellectual property portfolio through patent extensions and future potential indications of cytisinicline,” stated Rick Stewart, Chairman and Chief Executive Officer of Achieve.
Achieve said the patented analogs will now provide the opportunity for the selective targeting of nAChRs in the brain to treat several conditions such as Alzheimers disease, depression, anxiety schizophrenia, epilepsy, Parkinson's disease and addiction.
The company also separately announced that it has executed a 1:20 reverse split of its common stock.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .